Clarity Pharmaceuticals Ltd
Company Profile
Business description
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
Contact
2-4 Cornwallis Street
Suite 212a, National Innovation Centre
Eveleigh
SydneyNSW2015
AUST: +61 292094037
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
70
Clarity Pharmaceuticals Ltd News & Analysis
stocks
The ASX’s most shorted stocks
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,922.70 | 11.80 | 0.13% |
| CAC 40 | 8,065.02 | 121.91 | -1.49% |
| DAX 40 | 25,304.06 | 412.65 | -1.60% |
| Dow JONES (US) | 51,682.64 | 95.40 | -0.18% |
| FTSE 100 | 10,659.13 | 157.01 | -1.45% |
| HKSE | 24,750.78 | 146.49 | 0.60% |
| NASDAQ | 26,522.54 | 104.25 | 0.39% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,739.14 | 17.45 | -0.13% |
| S&P 500 | 7,650.50 | 12.74 | 0.17% |
| S&P/ASX 200 | 8,731.20 | 1.20 | -0.01% |
| SSE Composite Index | 3,911.87 | 36.27 | 0.94% |